Brain-derived vesicles
Brain cells release extracellular vesicles that reach biofluids (e.g. blood, urine, saliva…), carrying molecular cargo from their cell of origin.
Precision diagnostics in brain health
Decoding brain biology through biomarkers in biofluids.
MedPrecis develops extracellular-vesicle biomarker technologies to support earlier, more personalised care in psychiatric and neurodegenerative disorders.
Seen under the microscope
Exosomes, captured in brain tissue.
Electron microscopy shows multivesicular bodies releasing exosomes next to brain blood vessels: the biological signal our technology reads.
From brain to blood
A brain signal in a simple blood sample.
Vesicles released by brain cells reach the circulation, carrying proteins, microRNA and markers of their cell of origin.
Beyond blood
One technology, many biofluids.
Extracellular vesicles are found in plasma, serum, urine and saliva, opening the way to simple, less invasive and repeatable sampling.
Our platforms
One backbone, three platforms.
VESIDX, our indication-agnostic backbone, powers three modules: VESIBRAIN for neurology & psychiatry, VESIPATH for oncology and VESIGEN for systemic diseases.
01 / 05
The problem
Brain health lacks objective diagnostics
- In most of medicine, clinical evaluation is supported by objective tests.
- In brain health, access to objective biological signals is limited.
- Existing tools often provide late or non-specific information.
Our answer
Biology-based insight from a simple sample
- Analyses organ-derived biological signals from simple biofluid samples (e.g. blood, urine, saliva…).
- Captures disease mechanisms rather than isolated biomarkers.
- Translates biology into interpretable outputs for clinical decision support.
Earlier detection · Stratification · Treatment guidance
Why it matters
Brain health is one of the great medical challenges of our time
~15%
of the Swiss population is affected by a mental health disorder.
~1 billion
people worldwide live with a mental disorder.
37%
of young people report mental health problems.
Neurodegenerative diseases are a growing challenge as populations age. In Switzerland, Alzheimer’s disease is the most common form, followed by Parkinson’s disease.
Source: World Health Organization (WHO).
Our approach
Bridging neuroscience and precision medicine
We translate advances in brain biology into biomarker solutions that support diagnosis, patient selection and therapeutic development, always alongside clinical expertise.
Two biomarker classes
Proteins and microRNA are measured from the same enriched vesicle fraction.
Rigorous by design
Particle normalisation, calibration curves, controls and batch tracking at every step.
Discover our technology →Proven as a paid service
Already delivered as a paid analysis service in real-world research and clinical programmes, for leading academic centres and pharmaceutical partners.
Protected innovation
Patent families filed in Switzerland and the United States since 2019, covering key biomarkers, methods and clinical applications.
Global clinical network
An international network of clinicians and scientists supports validation and adoption.
Meet the team →Our platforms
One backbone, three platforms
VESIDX, our indication-agnostic backbone, powers three disease-focused platforms, from brain disorders to systemic health.
Indication-agnostic backbone
VESIDX
The common vesicle-analysis foundation behind every MedPrecis platform, also available as a flexible custom-detection solution for research and quality-control protocols.
Discover VESIDX →Neurology & psychiatry
VESIBRAIN
A companion test that brings brain-derived vesicle biomarkers into the assessment of psychiatric and neurological disorders.
Discover VESIBRAIN →Oncology
VESIPATH
Extracellular-vesicle analysis to explore the biological pathways of complex diseases, especially cancer.
Discover VESIPATH →Systemic & multi-organ
VESIGEN
A systemic view of health, using vesicles as messengers that reflect the state of organs and cells.
Discover VESIGEN →Applications
Supporting the next generation of therapeutic development
Patient stratification
Identify biologically meaningful patient subgroups to support precision-oriented clinical research.
Treatment-response research
Study molecular changes associated with therapeutic interventions and potential response biomarkers.
Translational biomarker development
Connect mechanistic neuroscience with biomarker discovery and clinical validation.
Events
IMHC 2026: 1st International Mental Health Conference
From help-seeking to precision medicine · 23–25 October 2026 · Tunis
Science-driven collaboration. Global ambition.
We work with academic researchers, clinical investigators, pharmaceutical companies and innovation partners to advance biomarker-driven neuroscience.